Adherex to collaborate with AstraZeneca

Adherex Technologies Inc, Ottawa, has entered a collaboration and option agreement with AstraZeneca plc to further develop the company’s cancer compounds including its lead compound, Exherin, as they move toward human trials. The collaboration begins with a preliminary six-month period during which AstraZeneca scientists will work with Adherex compounds. The collaboration may be extended but neither the terms nor the financial details of the pact are being disclosed….